Article

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of Concern

2022-01-19

Abstract excerpt

<h4>ABSTRACT</h4> New variants of SARS-CoV-2 with potential for enhanced transmission, replication, and immune evasion capabilities continue to emerge causing reduced vaccine efficacy and/or treatment failure. As of January 2021, the WHO has defined five ‘variants of concern’ (VOC): B.1.1.7 (Alpha, α), B.1.351 (Beta, β), P.1 (Gamma, γ), B.1.617.2 (Delta, δ), and B.1.1.529 (Omicron, o). To provide a therapeutic op...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 814de63c-8164-5064-9361-0421be38db14
DOI: 10.1101/2022.01.17.476644

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nirmatrelvir, an orally active Mpro inhibitor, is a potent inhibitor of SARS-CoV-2 Variants of ConcernDOI 10.1101/2022.01.17.476644Read

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to NirmatrelvirSemantic proximity Read

Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain ResistanceSemantic proximity Read

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent <i>in vitro</i> activity against the SARS-CoV-2 Omicron variantSemantic proximity Read

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsSemantic proximity Read

Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvirSemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read

Changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.Semantic proximity Read

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studySemantic proximity Read

Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332)Semantic proximity Read

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.Semantic proximity Read